Skip to main content

Table 2 BMD changes (g/cm2) in different parts before and after treatment

From: Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients

AreaTimeTreatment 1p*Treatment 2p*Controlp*
Lumbar1A.1.1.1.1.1.5. 0 M0.45 ± 0.250.49 ± 0.230.50 ± 0.18
A.1.1.1.1.1.6. 6 M0.50 ± 0.160.7850.48 ± 0.220.9830.52 ± 0.270.962
A.1.1.1.1.1.7. 12 M0.54 ± 0.19*0.0450.55 ± 0.230.6800.55 ± 0.280.785
Lumbar2A.1.1.1.1.1.8. 0 M0.65 ± 0.170.61 ± 0.120.64 ± 0.16
A.1.1.1.1.1.9. 6 M0.78 ± 0.22*0.0410.66 ± 0.130.5820.64 ± 0.170.992
A.1.1.1.1.1.10. 12 M0.72 ± 0.17*0.0490.67 ± 0.140.4600.63 ± 0.140.980
 A.1.1.1.1.1.11. 0 M0.69 ± 0.220.62 ± 0.240.70 ± 0.21
Lumbar3A.1.1.1.1.1.12. 6 M0.72 ± 0.130.9140.69 ± 0.290.5820.73 ± 0.160.914
 A.1.1.1.1.1.13. 12 M0.81 ± 0.17*0.0240.77 ± 0.25*0.0190.64 ± 0.270.699
 A.1.1.1.1.1.14. 0 M0.69 ± 0.180.65 ± 0.180.66 ± 0.16
Lumbar4A.1.1.1.1.1.15. 6 M0.74 ± 0.220.6640.67 ± 0.150.9290.65 ± 0.170.983
 A.1.1.1.1.1.16. 12 M0.90 ± 0.21*0.0110.68 ± 0.140.8480.63 ± 0.140.862
 A.1.1.1.1.1.17. 0 M0.54 ± 0.170.57 ± 0.140.57 ± 0.19
Ward areaA.1.1.1.1.1.18. 6 M0.66 ± 0.140.0760.54 ± 0.190.8320.54 ± 0.140.848
 A.1.1.1.1.1.19. 12 M0.80 ± 0.17*0.0120.67 ± 0.17*0.0360.50 ± 0.160.411
Femoral neckA.1.1.1.1.1.20. 0 M0.68 ± 0.130.63 ± 0.140.62 ± 0.20
A.1.1.1.1.1.21. 6 M0.84 ± 0.15*0.0140.65 ± 0.170.9260.65 ± 0.170.855
A.1.1.1.1.1.22. 12 M0.80 ± 0.21*0.0470.69 ± 0.17*0.5020.60 ± 0.170.933
  1. Note: *p values indicate the comparison with that before treatment within the same group; indicates p < 0.05 for the comparison between two groups at the same time point on their difference over the treatment